Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Thoracic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res. 2019 Dec 1;25(23):7113-7125. doi: 10.1158/1078-0432.CCR-19-1700. Epub 2019 Aug 30.
In patients with >1 non-small cell lung carcinoma (NSCLC), the distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is a common diagnostic dilemma with critical staging implications. Here, we compared the performance of comprehensive next-generation sequencing (NGS) with standard histopathologic approaches for distinguishing NSCLC clonal relationships in clinical practice.
We queried 4,119 NSCLCs analyzed by 341-468 gene MSK-IMPACT NGS assay for patients with >1 surgically resected tumor profiled by NGS. Tumor relatedness predicted by prospective histopathologic assessment was contrasted with comparative genomic profiling by subsequent NGS.
Sixty patients with NGS performed on >1 NSCLCs were identified, yielding 76 tumor pairs. NGS classified tumor pairs into 51 definite SPLCs (median, 14; up to 72 unique somatic mutations per pair), and 25 IPMs (24 definite, one high probability; median, 5; up to 16 shared somatic mutations per pair). Prospective histologic prediction was discordant with NGS in 17 cases (22%), particularly in the prediction of IPMs (44% discordant). Retrospective review highlighted several histologic challenges, including morphologic progression in some IPMs. We subsampled MSK-IMPACT data to model the performance of less comprehensive assays, and identified several clinicopathologic differences between NGS-defined tumor pairs, including increased risk of subsequent recurrence for IPMs.
Comprehensive NGS allows unambiguous delineation of clonal relationship among NSCLCs. In comparison, standard histopathologic approach is adequate in most cases, but has notable limitations in the recognition of IPMs. Our results support the adoption of broad panel NGS to supplement histology for robust discrimination of NSCLC clonal relationships in clinical practice.
在患有>1 个非小细胞肺癌(NSCLC)的患者中,区分多个原发性肺癌(SPLCs)和肺内转移(IPMs)是一个常见的诊断难题,具有关键的分期意义。在这里,我们比较了综合下一代测序(NGS)与标准组织病理学方法在临床实践中区分 NSCLC 克隆关系的性能。
我们查询了 341-468 基因 MSK-IMPACT NGS 分析的 4119 个 NSCLC,这些 NSCLC 来自通过 NGS 分析的>1 个手术切除肿瘤的患者。通过前瞻性组织病理学评估预测的肿瘤相关性与随后的 NGS 比较基因组分析进行对比。
确定了 60 名接受了>1 个 NSCLC NGS 检测的患者,产生了 76 对肿瘤。NGS 将肿瘤对分为 51 对明确的 SPLC(中位数为 14 个;每对最多有 72 个独特的体细胞突变)和 25 对 IPM(24 对明确,1 对高度可能;中位数为 5 个;每对最多有 16 个共享的体细胞突变)。前瞻性组织学预测与 NGS 在 17 例(22%)中不一致,特别是在 IPM 的预测中(44%不一致)。回顾性审查突出了几个组织学挑战,包括一些 IPM 中的形态进展。我们对 MSK-IMPACT 数据进行了亚采样,以模拟不太全面的检测的性能,并确定了 NGS 定义的肿瘤对之间的几个临床病理差异,包括 IPM 的后续复发风险增加。
综合 NGS 可明确区分 NSCLC 之间的克隆关系。相比之下,标准组织病理学方法在大多数情况下是足够的,但在识别 IPM 方面有明显的局限性。我们的结果支持采用广泛的面板 NGS 来补充组织学,以在临床实践中对 NSCLC 克隆关系进行稳健的区分。